See more : Oracle Corporation (ORC.DE) Income Statement Analysis – Financial Results
Complete financial analysis of Oryzon Genomics S.A. (0RDB.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Oryzon Genomics S.A., a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
- Jack Nathan Medical Corp. (JNHMF) Income Statement Analysis – Financial Results
- Ekennis Software Service Limit (EKENNIS.BO) Income Statement Analysis – Financial Results
- First Majestic Silver Corp. (FR.TO) Income Statement Analysis – Financial Results
- Idomoo Ltd. (IDMO.TA) Income Statement Analysis – Financial Results
- EirGenix Inc. (6589.TWO) Income Statement Analysis – Financial Results
Oryzon Genomics S.A. (0RDB.L)
About Oryzon Genomics S.A.
Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 15.67M | 16.81M | 12.08M | 11.63M | 11.53M | 7.77M | 5.18M | 5.27M | 7.80M | 18.81M | 3.25M | 4.35M |
| Cost of Revenue | 269.04K | 496.98K | 849.05K | 643.00K | 482.50K | 335.28K | 326.32K | 390.46K | 388.30K | 412.76K | 252.22K | 411.52K |
| Gross Profit | 15.40M | 16.31M | 11.23M | 10.99M | 11.05M | 7.43M | 4.85M | 4.88M | 7.41M | 18.39M | 3.00M | 3.94M |
| Gross Profit Ratio | 98.28% | 97.04% | 92.97% | 94.47% | 95.81% | 95.68% | 93.70% | 92.59% | 95.02% | 97.81% | 92.24% | 90.55% |
| Research & Development | 6.88M | 7.10M | 8.37M | 5.96M | 5.40M | 4.70M | 7.60M | 7.76M | 6.83M | 6.95M | 1.74M | 454.82K |
| General & Administrative | 4.25M | 0.00 | 0.00 | 0.00 | 0.00 | 665.60 | 0.00 | 2.17K | 1.86K | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | -265.94K | 0.00 | 0.00 | 0.00 | 0.00 | 3.09M | 0.00 | 2.58M | 2.06M | 0.00 | 0.00 | 0.00 |
| SG&A | 3.98M | 3.82M | 4.18M | 4.51M | 3.75M | 3.54M | 3.76M | 2.71M | 2.24M | 2.45M | 1.58M | 1.71M |
| Other Expenses | 9.56M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 20.42M | 22.15M | 18.89M | 16.25M | 15.33M | 10.77M | 10.23M | 9.69M | 7.76M | 9.47M | 5.74M | -4.07M |
| Cost & Expenses | 20.69M | 22.64M | 19.74M | 16.90M | 15.81M | 11.10M | 10.56M | 10.08M | 8.15M | 9.88M | 5.99M | -3.66M |
| Interest Income | 1.32M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 1.19M | 512.49K | 572.88K | 847.74K | 916.98K | 923.70K | 962.03K | 687.83K | 764.25K | 434.90K | -570.81K |
| Depreciation & Amortization | 143.67K | 156.97K | 151.54K | 162.00K | 155.08K | 159.51K | 195.09K | 192.01K | 234.35K | 277.16K | 2.12M | -751.58K |
| EBITDA | -4.89M | -5.73M | -7.83M | -5.08M | -4.15M | -3.55M | -5.48M | -5.02M | -548.79K | 12.23M | -932.35K | 141.21K |
| EBITDA Ratio | -31.24% | -34.08% | -64.81% | -43.67% | -35.96% | -45.68% | -105.81% | -95.17% | -7.03% | 65.01% | -28.68% | 3.24% |
| Operating Income | -5.02M | -5.89M | -7.98M | -5.24M | -4.30M | -3.71M | -5.68M | -5.21M | -783.13K | 11.95M | -3.05M | -610.37K |
| Operating Income Ratio | -32.06% | -35.02% | -66.07% | -45.06% | -37.31% | -47.73% | -109.58% | -98.81% | -10.04% | 63.53% | -93.98% | -14.02% |
| Total Other Income/Expenses | -1.72M | -1.13M | -189.75K | -596.33K | -832.31K | -911.67K | -1.11M | -949.54K | -784.16K | 744.49K | -436.38K | -87.60K |
| Income Before Tax | -6.74M | -7.02M | -8.17M | -5.84M | -5.13M | -4.25M | -6.30M | -5.77M | -1.04M | 8.16M | -3.18M | -697.98K |
| Income Before Tax Ratio | -43.01% | -41.77% | -67.64% | -50.19% | -44.53% | -54.74% | -121.66% | -109.39% | -13.29% | 43.38% | -97.75% | -16.03% |
| Income Tax Expense | 3.04M | 2.49M | 2.84M | 1.68M | 1.00M | 2.90M | 66.04K | 33.23K | 40.13K | 107.09K | 204.61K | 89.68K |
| Net Income | -3.70M | -4.53M | -5.33M | -4.15M | -4.13M | -1.35M | -6.24M | -5.73M | -1.08M | 8.05M | -2.97M | -608.29K |
| Net Income Ratio | -23.63% | -26.95% | -44.15% | -35.71% | -35.85% | -17.36% | -120.38% | -108.76% | -13.81% | 42.81% | -91.45% | -13.97% |
| EPS | -0.06 | -0.08 | -0.10 | -0.08 | -0.09 | -0.04 | -0.19 | -0.21 | -0.04 | 0.30 | -0.13 | -0.03 |
| EPS Diluted | -0.06 | -0.08 | -0.10 | -0.08 | -0.09 | -0.04 | -0.19 | -0.21 | -0.04 | 0.30 | -0.13 | -0.03 |
| Weighted Avg Shares Out | 60.88M | 55.29M | 52.76M | 52.76M | 45.49M | 38.46M | 32.48M | 27.72M | 27.49M | 26.52M | 23.20M | 23.20M |
| Weighted Avg Shares Out (Dil) | 60.88M | 55.29M | 52.76M | 52.76M | 45.49M | 38.45M | 32.48M | 27.72M | 27.49M | 26.52M | 23.20M | 23.20M |
Source: https://incomestatements.info
Category: Stock Reports